DUBLIN – (BUSINESS WIRE) – “Virtual Clinical Trials Market Research Report according to study design (extended access trials, intervention trials and observational trials), implication (cardiovascular disease and oncology) – Global outlook to 2025 – cumulative effect of COVID-19 added in ResearchAndMarkets.com’s offer.
The global market for virtual clinical trials is expected to grow from $ 2,092.67 million in 2020 to $ 5,521.67 million by the end of 2025.
Cumulative impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so the long-term and projected effects will affect the growth of the industry over the projected period. Our ongoing research strengthens our research framework to ensure the inclusion of fundamental COVID-19 issues and potential pathways forward.
The report provides insight into COVID-19 in light of changes in consumer behavior and demand, purchasing patterns, supply chain reorientation, the dynamics of current market forces, and significant government intervention. The updated study provides insight, analysis, estimates and forecasts, taking into account the impact of COVID-19 on the market.
FPNV positioning matrix:
The FPNV positioning matrix assesses and categorizes suppliers in the virtual clinical trial market based on business strategy (business growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features, and customer support) that helps businesses in better decision making and understanding of the competitive environment.
Strategic competition window:
The Strategic Competition Window analyzes the competitive landscape in terms of markets, applications, and geographic areas. The strategic competition window helps the supplier to define the alignment or fit between its capabilities and the prospects for future growth prospects.
During the envisaged period, it defines the optimal or favorable suitability of suppliers to adopt successive merger and acquisition strategies, geographical expansion, research and development and new product introduction strategies for further expansion and growth of the business.
1.1. Objectives of the study
1.2. Market segmentation and coverage
1.3. Years considered for study
1.4. Currency and prices
2. Research methodology
2.1. Research process
2.2. Execution of research
2.3. Research outcome
3.2. Market Outlook
3.3. Outlook Design Outlook
3.4. Implication Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. Market overview
4.2. Cumulative impact of COVID-19
5. Market insight
5.1. Market dynamics
22.214.171.124. Increasing adoption of telehealth
126.96.36.199. The growing adoption of digitalization in healthcare globally
188.8.131.52. Proliferation of research and development activities, together with favorable government support
184.108.40.206. Concerns about high data collection, accuracy and reliability of data, and technological failure
220.127.116.11. Current technological advances in healthcare
18.104.22.168. New collaboration between biotechnology companies and clinical research companies
22.214.171.124. A cumbersome and difficult process with enrollment and engagement
5.2. Five-force carrier analysis
5.2.1. Threat to new participants
5.2.2. Threat of replacements
5.2.3. Negotiating power of customers
5.2.4. Vendor bargaining power
5.2.5. Industrial rivalry
6. Global market of virtual clinical trials, according to the study design
6.2. Extended access experiments
6.3. Interventional trials
6.4. Observational examinations
7. Global market for virtual clinical trials, implied
7.2. Cardiovascular diseases
8. U.S. Virtual Clinical Trials Market
8.6. United States
9. Asia-Pacific Virtual Clinical Trials Market
9.9. north korea
10. Virtual Clinical Trials Market for Europe, the Middle East and Africa
10.5. The Netherlands
10.8. Saudi Arabia
10.9. South Africa
10.11. United Arab Emirates
11. Competitive landscape
11.1. FPNV positioning matrix
11.1.2. Business strategy
11.1.3. Product satisfaction
11.2. Market ranking analysis
11.3. Market share analysis
11.4. SWOT analysis of the competitor
11.5. Competitive scenario
11.5.1. Merger and acquisition
11.5.2. Agreement, cooperation and partnership
11.5.3. Launch and improvement of a new product
11.5.4. Investments and financing
11.5.5. Award, recognition and expansion
12. Useful company profiles
12.1. AiCure LLC
12.2. Clinical ink by a GI partner
12.3. CliniOps, Inc.
12.4. Covance Inc.
12.5. CRF Health By Genstar Capital
12.7. Everest Global, Inc.
12.8. ICON PLC
12.10. LEO Innovation Lab
12.11. Medable, Inc.
12.12. Medidata Solutions
12.14. Navitas Life Sciences, Inc.
12.15. Neoteryx, LLC
12.16. Oracle Corporation
12.17. Parexel International
12.18. Pfizer Inc.
12.19. Science 37
12.20. Tenthpin Management Consultants AG
12.21. VirTrial, LLC
For more information on this report, visit https://www.researchandmarkets.com/r/eibu93